Asad Haider
Stock Analyst at Goldman Sachs
(2.86)
# 1,578
Out of 5,127 analysts
15
Total ratings
71.43%
Success rate
20.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $108.93 | +30.36% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $238.35 | +0.69% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $34.89 | +6.05% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $60.86 | -6.34% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $21.84 | -22.16% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $44.21 | -5.00% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $54.98 | -30.88% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,025.00 | -13.37% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $222.44 | -12.79% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $27.61 | -9.45% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $108.93
Upside: +30.36%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $238.35
Upside: +0.69%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $34.89
Upside: +6.05%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $60.86
Upside: -6.34%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $21.84
Upside: -22.16%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $44.21
Upside: -5.00%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $54.98
Upside: -30.88%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,025.00
Upside: -13.37%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $222.44
Upside: -12.79%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $27.61
Upside: -9.45%